VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ZVRAZevra Therapeutics, Inc.
$13.52$799M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksZVRAEarnings History

ZVRA logoZevra Therapeutics, Inc. (ZVRA) Earnings History

Profitable

14 years of earnings data (2012–2025) · Positive TTM net income

TTM Net Income
$124M
● Profitable
TTM EPS (Diluted)
$2.06
Per share, diluted
YoY EPS Growth
+159.2%
Excellent
Net Margin
78.2%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-4.0%
Gross Margin84.5%
Return on Equity85.7%
Return on Assets36.0%
Record Annual Net Income$83MFY2025
Record Quarterly EPS$1.36Q2 2025
Consecutive Profitable Years1years
Q1 2026
Net Income$38M
EPS (Diluted)$0.60
YoY Growth+159.2%Excellent
QoQ Growth+211.5%Excellent

Loading earnings history...

Zevra Therapeutics, Inc. (ZVRA) Earnings Overview

As of June 28, 2026, Zevra Therapeutics, Inc. (ZVRA) reported trailing twelve-month net income of $124M, reflecting +159.2% year-over-year growth. The company earned $2.06 per diluted share over the past four quarters, with a net profit margin of 78.2%.

Looking at the long-term picture, ZVRA's historical earnings data spans multiple years. The company achieved its highest annual net income of $83M in fiscal 2025, representing a new all-time high.

Zevra Therapeutics, Inc. maintains industry-leading profitability with a gross margin of 84.5%, operating margin of -4.0%, and net margin of 78.2%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →

Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), ACAD ($376M net income, 36.5% margin), ZVRA has outperformed on profitability metrics. Compare ZVRA vs RARE →

ZVRA Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ZVRA logoZVRACurrent
$124M$2.0678.2%85.7%+159.2%—
RARE logoRARE
-$609M$-6.06-85.4%-607.5%+7.3%
FOLD logoFOLD
-$27M$-0.09-4.3%-11.6%+51.2%
ACAD logoACAD
$376M$2.1836.5%39.9%+68.4%
PTCT logoPTCT
-$187M$-2.2639.4%-+264.5%
KRYS logoKRYS
$225M$7.3852.6%18.9%+128.0%
Best in group
Lowest in group

ZVRA Historical Earnings Data (2012–2025)

14 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$83M+178.9%-$4M$1.3578.2%-4.0%
2024-$106M-129.1%-$87M$-2.28-446.9%-368.5%
2023-$46M-72.0%-$50M$-1.30-167.7%-180.6%
2022-$27M-212.9%-$43M$-0.78-263.5%-418.9%
2021-$9M+33.0%$8M$-2.11-29.9%27.0%
2020-$13M+48.0%-$6M$-3.21-96.0%-42.2%
2019-$25M+56.6%-$20M$-13.23-191.0%-158.4%
2018-$56M-30.1%-$56M$-50.39--
2017-$43M-162.7%-$33M$-47.37--
2016-$17M+69.8%-$37M$-18.10--
2015-$55M-123.5%-$23M$-118.69--
2014-$24M-367.9%-$16M$-31.79--
2013-$5M-7321.6%-$5M$-10.69--
2012$-70,416--$5M$-0.47--

Download Data

Export ZVRA earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ZVRA — Frequently Asked Questions

Quick answers to the most common questions about buying ZVRA stock.

What is ZVRA earnings per share (EPS)?

ZVRA trailing twelve-month (TTM) diluted EPS is $2.06, reflecting +159.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.

What is Zevra Therapeutics, Inc.'s net income?

Zevra Therapeutics, Inc. (ZVRA) trailing twelve-month net income is $124M as of 2025. Earnings grew +159.2% year-over-year.

Is ZVRA profitable?

Yes, ZVRA is profitable with a TTM net income of $124M and a net profit margin of +78.2%.

What is ZVRA's earnings growth rate?

ZVRA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.

What are ZVRA's profit margins?

Zevra Therapeutics, Inc. net profit margin is +78.2%, operating margin is -4.0%, and gross margin is +84.5%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +85.7%.

Is ZVRA growing earnings?

Yes, ZVRA earnings are accelerating — EPS growth of +159.2% exceeds the 5-year CAGR of N/A. TTM net income reached $124M. Earnings momentum is strengthening.

What was ZVRA's best earnings year?

Zevra Therapeutics, Inc.'s highest annual net income on record is $83M, achieved in fiscal year 2025. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.

What were ZVRA's earnings last quarter?

ZVRA's most recent reported quarter was Q1 2026. Net income was $38M with diluted EPS of $0.60. For a full breakdown of all quarters, see the quarterly earnings table on this page.

ZVRA Earnings Over Time (2012–2025)

Net income & EPS — annual and quarterly view